Patients with metastatic BRAF V600 mutant melanoma, which accounts for 40–50% of melanoma patients, are treated with MEK inhibitors such as trametinib, cobimetinib, selumetinib, and binimetinib [70]. The gene discussed is BRAF; the disease is melanoma.